Does linezolid modulate lung innate immunity in a murine model of methicillin-resistant Staphylococcus aureus pneumonia?

Critical Care Medicine

Volumn 39, Issue 8, 2011, Pages 1944-1952

  Akinnusi, Morohunfolu E ^b   Hattemer, Angela ^b   Gao, Wei ^b   El Solh, Ali A ^a,b,c  

^a VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^b Division of Pulmonary and Critical Care Medicine   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

innate immunity; Linezolid; murine model; pneumonia; Staphylococcus aureus; vancomycin

Indexed keywords

7 AMINODACTINOMYCIN; GELATINASE B; INTERLEUKIN 6; LINEZOLID; LIPOCORTIN 5; MONOCYTE CHEMOTACTIC PROTEIN 5; MYELOPEROXIDASE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOUSE; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; ZYMOGRAPHY;

EID: 79961021455     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31821bd79e     Document Type: Article

References (44)

1. Kollef MH: Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit Care Med 2004; 32:1396-1405 (Pubitemid 38738598)
2. Richards MJ, Edwards JR, Culver DH, et al: Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27:887-892 (Pubitemid 29266004)
3. Rello J, Ollendorf DA, Oster G, et al: Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002; 122:2115-2121 (Pubitemid 36051151)
4. Warren DK, Shukla SJ, Olsen MA, et al: Outcome and attributable cost of ventilatorassociated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003; 31:1312-1317 (Pubitemid 36583837)
5. Kuehnert MJ, Hill HA, Kupronis BA, et al: Methicillin-resistant- Staphylococcus aureus hospitalizations, United States. Emerg Infect Dis 2005; 11:868-872 (Pubitemid 40720847)
6. American Thoracic Society; Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcareassociated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416
7. Betriu C, Redondo M, Palau M, et al: Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and-resistant streptococci. Antimicrob Agents Chemother 2000; 44:1838-1841 (Pubitemid 30422933)
8. Rybak M, Hershberger E, Moldovan T, et al: In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and 0resistant strains. Antimicrob Agents Chemother 2000; 44:1062-1066 (Pubitemid 30165292)
9. Drago L, De Vecchi E, Valli M, et al: Effect of linezolid in comparison with that of vancomycin on glycocalix production: in vitro study. Antimicrob Agents Chemother 2002; 46:598-599 (Pubitemid 34087226)
10. Bernardo K, Pakulat N, Fleer S, et al: Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 2004; 48:546-555 (Pubitemid 38141715)
11. Powers JH, Ross DB, Lin D, Soreth J: Linezolid and vancomycin for methicillinresistant Staphylococcus aureus nosocomial pneumonia: The subtleties of subgroup analyses. Chest 2004; 126:314-315
12. Kalil AC, Puumala SE, Stoner J: Unresolved questions with the use of linezolid vs vancomycin for nosocomial pneumonia. Chest 2004; 125:2370-2371 (Pubitemid 38788219)
13. Wunderink RG, Rello J, Cammarata SK, et al: Linezolid versus vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789-1797 (Pubitemid 37433574)
14. Kollef MH, Rello J, Cammarata SK, et al: Clinical cure and survival in Gram-positive ventilator-associated pneumonia: Retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30:388-394 (Pubitemid 38375611)
15. Wunderink R, Mendelson M, Somero M, et al: Early microbiological response to linezolid vs vancomycin in ventilator associated pneumonia due to methicillin resistant Staphylococcus aureus. Chest 2008; 134:1200-1207
16. Garcia-Roca P, Mancilla-Ramirez J, Santos-Segura A, et al: Linezolid diminishes inflammatory cytokine production from human peripheral blood mononuclear cells. Arch Med Res 2006; 37:31-35 (Pubitemid 41727888)
17. Clinical and Laboratory Standards Institute: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Sixth Edition. Approved Standard M7-A6. Wayne, PA, CLSI, 2006
18. Skerrett SJ, Liggitt HD, Hajjar AM, et al: Cutting edge: Myeloid differentiation factor 88 is essential for pulmonary host defense against Pseudomonas aeruginosa but not Staphylococcus aureus. J Immunol 2004; 172:3377-3381 (Pubitemid 38337914)
19. Shaw J, Adams S, Li D, et al: Preclinical pharmacokinetics and allometric scaling of vancomycin. AAPS Pharm Sci 2002; 4:T3252
20. Slatter JG, Adams LA, Bush EC, et al: Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 2002; 32: 907-924 (Pubitemid 35155524)
21. Hibbs MS, Hasty KA, Seyer JM, et al: Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase. J Biol Chem 1985; 260: 2493-2500 (Pubitemid 15104858)
22. Klebanoff SJ: Myeloperoxidase. Proc Assoc Am Phys 1999; 111:383-389 (Pubitemid 29446879)
23. Shellito J, Kaltreider HB: Heterogeneity of immunologic function among subfractions of normal rat alveolar macrophages. Am Rev Respir Dis 1984; 129:747-753 (Pubitemid 14104755)
24. Van Epps D, Garcia M: Enhancement of neutrophil function as a result of prior exposure to chemotactic factor. J Clin Invest 1980; 66:167-175 (Pubitemid 10092612)
25. Savill J, Dransfield I, Hogg N, et al: Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature 1990; 343: 170-173
26. Bianchi SM, Prince LR, McPhillips K, et al: Impairment of apoptotic cell engulfment by pyocyanin, a toxic metabolite of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2008; 177:35-43
27. Watt AP, Courtney J, Moore J, et al: Neutrophil cell death, activation and bacterial infection in cystic fibrosis. Thorax 2005; 60: 659-664 (Pubitemid 41129064)
28. Gordon SB, Irving GRB, Lawson RA, et al: Intracellular trafficking and killing of Streptococcus pneumoniae by human alveolar macrophages are influenced by opsonins. Infect Immun 2000; 68:2286-2293 (Pubitemid 30165719)
29. Nelson S, Summer WR: Innate immunity, cytokines and pulmonary host defense. Infect Dis Clin North Am 1998; 12:555-567. (Pubitemid 28461419)
30. Dusi S, Bianca VD, Donini M, et al: Mechanisms of stimulation of the respiratory burst by TNF in nonadherent neutrophils: Its independence of lipidic transmembrane signalling and dependence on protein tyrosine phosphorylation and cytoskeleton. J Immunol 1996; 157:4615-4623. (Pubitemid 126449384)
31. Rogers HW, Tripp CS, Schreiber RD, et al: Endogenous IL-1 is required for neutrophil recruitment and macrophage activation during murine listeriosis. J Immunol 1994; 153: 2093-2101 (Pubitemid 24256680)
32. Mullen PG, Windsor ACJ, Fowler AA, et al: Tumor necrosis factor α and interleukin-6 selectively regulate neutrophil function in vitro. J Surg Res 1995; 58:124-130
33. Opdenakker G, Van den Steen PE, Dubois B, et al: Gelatinase B functions as regulator and effector in leukocyte biology. J Leukocyte Biol 2001; 69:851-859 (Pubitemid 32577883)
34. Takahashi G, Sato N, Yaegashi Y, et al: Effect of linezolid on cytokine production capacity and plasma endotoxin levels in response to lipopolysaccharide stimulation of whole blood. J Infect Chemother 2010; 16:94-99
35. Luna C, Bruno D, Garcia-Morato J, et al: Effect of linezolid compared with glycopeptides in methicillin-resistant Staphylococcus aureus severe pneumonia in piglets. Chest 2009; 135:1564-1571
36. Yang S, Chu S, Chiang I, et al: Excessive matrix metalloproteinase-9 in the plasma of community-acquired pneumonia. Clin Chim Acta 2005; 352:209-215 (Pubitemid 40093873)
37. Hartog CM, Wermelt JA, Sommerfeld CO, et al: Pulmonary matrix metalloproteinase excess in hospital-acquired pneumonia. Am J Respir Crit Care Med 2003; 167:593-598
38. Chakrabarti S, Patel KD: Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology. Exp Lung Res 2005; 31:599-621 (Pubitemid 40967244)
39. Matsubara M, Girard MT, Kublin CL, et al: Differential roles for two gelatinolytic en-zymes of the matrix metalloproteinase family in the remodeling cornea. Dev Biol 1991; 147:425-432
40. Mohan R, Sivak J, Ashton P, et al: Curcuminoids inhibit the angiogenic response stimulated by FGF-2 including expression of matrix metalloproteinase gelatinase B. J Biol Chem 2000; 275:10405-10412 (Pubitemid 30202100)
41. Yu Q, Stamenkovic I: Localization of metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999; 13:35-48 (Pubitemid 29045114)
42. Savill J, Dransfield I, Gregory C, et al: A blast from the past: Clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002; 2:965-975 (Pubitemid 37323217)
43. Kunkel M, Chastre JE, Kollef M, et al: Linezolid vs. vancomycin in the treatment of nosocomial pneumonia proven due to methicillin-resistant Staphylococcus aureus (oral abstract). Presented at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA); October 21-24, 2010; Vancouver, BC, Canada
44. Honeybourne D, Tobin C, Jevons G, et al: Intrapulmonary penetration of linezolid. J Antimicrob Chemother 2003; 51:1431-1434 (Pubitemid 36748935)